Genetic susceptibility to prostate cancer;Facteurs de risque génétiques pour le cancer de la prostate

Medecine/Sciences

Volumn 20, Issue 5, 2004, Pages 562-568

  Cussenot, Olivier ^a   Cancel Tassin, Géraldine ^b  

^a HÔPITAL TENON   (France)

^b CeRePP/EA3104 Paris 7 ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE DISTRIBUTION; ALLELISM; CANCER INCIDENCE; CANCER RISK; CANCER SUSCEPTIBILITY; CELL DIFFERENTIATION; CELL PROLIFERATION; FAMILY HISTORY; FAMILY STUDY; GENE LOCUS; GENE MUTATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENOTYPE; HEREDITY; HIGH RISK POPULATION; HUMAN; MALE; PROSTATE CARCINOMA; RACE; REVIEW;

EID: 2442600196     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/2004205562     Document Type: Review

References (35)

1. http://www-dep.iarc.fr, 2000.
2. Labrie F, Candas B, Dupont A, et al. Screening decreases prostate cancer death: First analysis of the 1988 Quebec prospective randomized controlled trial. Prostate 1999; 38: 83-91.
3. Cussenot O, Valeri A. Heterogeneity in genetic susceptibility to prostate cancer. Eur J Intern Med 2001; 12: 11-6.
4. Cussenot O, Fournier G. Génétique et urologie. Paris: les Éditions Vingt et un. Progrès en Urologie 2000: 417p.
5. Morganti G, Gianferrari L, Cresseri A, et al. Recherches clinico-statistiques et génétiques sur les néoplasies de la prostate. Acta Genet Stat Med 1956; 6: 304-5.
6. Grönberg H, Damber L, Damber JE. Studies of genetic factors in prostate cancer in twin population. J Urol 1994; 152: 1484-9.
7. Schaid DJ, McDonnell SK, Blute ML, et al. Evidence for autosomal dominant inheritance of prostate cancer. Am J Hum Genet 1998; 62: 1425-38.
8. Carter BS, Beaty TH, Steinberg GD, et al. Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992; 89: 3367-71.
9. Xu J and the International consortium for prostate cancer genetics. Combined analysis of hereditary prostate cancer linkage to 1q24-25: results from 772 hereditary prostate cancer families from the International consortium for prostate cancer genetics. Am J Hum Genet 2000; 66: 945-57.
10. Berthon P, Valeri A, Cohen-Akenine A, et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am J Hum Genet 1998; 62: 1416-24.
11. Cancel-Tassin G, Latil A, Valeri A, et al. PCAP is the major known prostate cancer predisposing locus in families from south and west Europe. Eur J Hum Genet 2001; 9: 135-42.
12. Karayi MK, Neal DE, Markham AF. Current status of linkage studies in hereditary prostate cancer. BJU Int 2000; 86: 659-69.
13. Valeri A, Azzouzi R, Drelon E, et al. Early-onset hereditary prostate cancer is not associated with specific clinical biological features. Prostate 2000; 45: 66-71.
14. Goode EL, Stanford JL, Peters MA, et al. Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci. Clin Cancer Res 2001; 7: 2739-49.
15. Bratt O. Hereditary prostate cancer: Clinical aspects. J Urol 2002; 168: 906-13.
16. Valeri A, Fournier G, Morin V, et al. Early onset and familial predisposition to prostate cancer significantly enhance the probability for breast cancer in first degree relatives. Int J Cancer 2000; 86: 883-7.
17. Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet 2003; 72: 1-12.
18. Gayther SA, de Foy KA, Harrington P, et al. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The cancer research campaign/British prostate group united kingdom familial prostate cancer study collaborators. Cancer Res 2000; 60: 4513-8.
19. Jonsson BA, Bergh A, Stattin P, et al. Germline mutations in E-cadherin do not explain association of hereditary prostate cancer, gastric cancer and breast cancer. Int J Cancer 2002; 98: 838-43.
20. Ross RK, Pike MC, Coetzee GA, et al. Androgen metabolism and prostate cancer: Establishing a model of genetic susceptibility. Cancer Res 1998; 58: 4497-504.
21. Bosland MC. The role of steroid hormones in prostate carcinogenesis. J Natl Cancer Inst Monogr 2000; 27: 39-66.
22. Irvine RA, Yu MC, Ross RK, et al. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer. Cancer Res 1995; 55: 1937-40.
23. Edwards A, Hammond HA, Jin L, et al. Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups. Genomics 1992; 12: 241-53.
24. Rebbeck TR, Jaffe JM, Walker AH, et al. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 1998; 90: 1225-9.
25. Lunn RM, Bell DA, Mohler JL, et al. Prostate cancer risk and polymorphism in 17 hydroxylase (CYP17) and steroid reductase (SRD5A2). Carcinogenesis 1999; 20: 1727-31.
26. Chang BL, Zheng SL, Hawkins GA, et al. Joint effect of HSD3B1 and HSD3B2 genes is associated with hereditary and sporadic prostate cancer susceptibility. Cancer Res 2002; 62: 1784-9
27. Lotil A, Azzouzi R, Cancel G, et al. Prostate carcinoma risk and allelic variants of genes involved in androgen biosynthesis and metabolism pathways. Cancer 2001; 92: 1130-7.
28. Cancel-Tassin G, Lotil A, Rousseau F, et al. Association study of polymorphisms in the human estrogen receptor alpha gene and prostate cancer risk. Eur Urol 2003; 44: 487-90.
29. Tang YM, Green BL, Chen GF, et al. Human CYP1B1 Leu432Val gene polymorphism: ethnic distribution in African-Americans, Caucasians and Chinese; oestradiol hydroxylase activity; and distribution in prostate cancer cases and controls. Pharmacogenetics 2000; 10: 761-6.
30. Correa-Cerro L, Berthon P, Houssler J, et al. Vitamin D receptor polymorphisms as markers in prostate cancer. Human Genet 1999; 105: 281-7.
31. Reszka E, Wasowicz W. Genetic polymorphism of N-acetyltransferase and glutathione S-transferase related to neoplasm of genitourinary system. Neoplasma 2002; 49: 209-16.
32. Simard J, Dumont M, Soucy P, et al. Perspective: prostate cancer susceptibility genes. Endocrinology 2002; 143: 2029-40.
33. Nwosu V, Carpten J, Trent JM, et al. Heterogeneity of genetic alterations in prostate cancer: Evidence of the complex nature of the disease. Hum Mol Genet 2001; 10: 2313-8.
34. Valeri A, Cormier L, Moineau MP, et al. Targeted screening for prostate cancer in high risk families: Early onset is a significant risk factor for disease in first degree relatives. J Urol 2002; 168: 483-7.
35. Novelli G, Margiotti K, Sangiuolo F, et al. Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics 2001; 2: 65-72.